Royal Bank of Canada
DYN icon

Royal Bank of Canada’s Dyne Therapeutics DYN Stock Holding History

Royal Bank of Canada’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.24M Buy
68,188
+49,641
+268% +$856K ﹤0.01% 3459
2025
Q4 		$363K Sell
18,547
-524,619
-97% -$9.93M ﹤0.01% 4398
2025
Q3 		$6.87M Buy
543,166
+168,197
+45% +$1.92M ﹤0.01% 2422
2025
Q2 		$3.57M Buy
374,969
+374,234
+50,916% +$4.12M ﹤0.01% 2849
2025
Q1 		$8K Sell
735
-1,382
-65% -$19.8K ﹤0.01% 6219
2024
Q4 		$50K Sell
2,117
-7,590
-78% -$225K ﹤0.01% 5693
2024
Q3 		$349K Buy
9,707
+1,619
+20% +$64.4K ﹤0.01% 4383
2024
Q2 		$285K Buy
8,088
+3,069
+61% +$89.2K ﹤0.01% 4461
2024
Q1 		$143K Sell
5,019
-9,415
-65% -$213K ﹤0.01% 4959
2023
Q4 		$191K Buy
14,434
+6,424
+80% +$62.8K ﹤0.01% 5142
2023
Q3 		$71K Buy
8,010
+2,932
+58% +$31.6K ﹤0.01% 5584
2023
Q2 		$57K Buy
5,078
+2,140
+73% +$25.2K ﹤0.01% 5709
2023
Q1 		$33K Sell
2,938
-1,796
-38% -$23.3K ﹤0.01% 5828
2022
Q4 		$55K Buy
4,734
+3,185
+206% +$36.9K ﹤0.01% 5822
2022
Q3 		$20K Buy
1,549
+208
+16% +$2.38K ﹤0.01% 6135
2022
Q2 		$9K Sell
1,341
-1,668
-55% -$11.5K ﹤0.01% 6419
2022
Q1 		$29K Sell
3,009
-4,429
-60% -$37.7K ﹤0.01% 6398
2021
Q4 		$88K Buy
7,438
+2,492
+50% +$35K ﹤0.01% 6023
2021
Q3 		$81K Buy
4,946
+2,886
+140% +$51.2K ﹤0.01% 5851
2021
Q2 		$43K Buy
2,060
+518
+34% +$9.74K ﹤0.01% 6134
2021
Q1 		$24K Buy
1,542
+886
+135% +$17.1K ﹤0.01% 6324
2020
Q4 		$14K Buy
+656
New +$13K ﹤0.01% 6220

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Royal Bank of Canada's DYN Position: Q1 2026 in Review

Royal Bank of Canada increased its Dyne Therapeutics (DYN) stake by 268% in Q1 2026, buying an estimated $856K and bringing the position to 68,188 shares worth $1.24M. The position accounts for ﹤0.01% of the portfolio, ranked #3459.

Royal Bank of Canada first reported a position in DYN in Q4 2020 and has held it in 22 quarters since. The position peaked at $6.87M in Q3 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Royal Bank of Canada held 68,188 shares of Dyne Therapeutics worth $1.24M as of Q1 2026.
  • Royal Bank of Canada bought 49,641 Dyne Therapeutics shares in Q1 2026, an estimated $856K.
  • Dyne Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #3459 holding.
  • Royal Bank of Canada first reported a position in Dyne Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Royal Bank of Canada's Dyne Therapeutics position peaked at $6.87M in Q3 2025.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.